POLIO: NEW CHALLENGES ON THE WAY TO ERADICATION

Authors

  • V. Z. Zadorozhna The L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases
  • O. M. Tsyganchuk The L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases

DOI:

https://doi.org/10.11603/1681-2727.2016.4.7206

Keywords:

poliomyelitis, eradication.

Abstract

SUMMARY. Despite the undeniable progress on the implementation of the Global Initiative eradication of poliomyelitis (polio cases have decreased by over 99,9 % since 1988, the cessation of circulation «wild» polioviruses types 1 and 3, the number of polio-endemic countries had decreased from 125 to 3, etc.), a number of outstanding issues remain that prevents the achievement of the ultimate goal (the continued circulation of the «wild» poliovirus type 1, the formation of vaccine derived polioviruses (VDPVs) and associated risks, cases of vaccine associated paralytic poliomyelitis (VAPP), gaps in immunization programs of certain countries and others. In 2015 in Ukraine there was an outbreak of poliomyelitis caused circulating VDPV1 (cVDPV1). This happened against the backdrop of years of decline coverage planned vaccination against poliomyelitis (for example, in 2014 ‒ 44.7 %, 7 months of 2015 ‒ 17.3 %). This contributed to the accumulation of non-immune interlayer among children and the formation VDPVs. In response to the polio outbreak was conducted three rounds of immunization by OPV. However, their levels were inadequate (respectively 64.4 %, 71.7 % and 80.7 % compared with the required 95 %). At the same time, the results of surveillance showed high probability of termination circulation cVDPV1.

References

WHO. (2016). Polio vaccines: WHO position paper – March, 2016. Weekly Epidemiological Record, 91(12), 145-168.

Sutter, R. W., Kew, O. M., Cochi, S. L., Aylward, B. (2013). Poliovirus vaccine  live. In S. A. Plotkin, W. A. Orenstein, P. A. Offit (Eds.), Vaccines: 6th ed. (рр. 598-645). Edinburgh, United Kingdom: Elsevier/Saunders.

WHO: Report of the 30th Meeting of the European Regional Certification Commission for Poliomyelitis Eradication (31 May to 2 June 2016) (2016).Copenhagen, Denmark.

WHO. (2016). Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2016. Weekly Epidemiological Record, 91(47), 556-560.

Kew, O. M., Wright, P. F., Agol, V. I. (2004). Circulating vaccine-derived polioviruses: current state of knowledge. Bull. WHO, 82(1). Retrieved from http://www.scielosp.org/scielo.php?script=sci_arttext&pid =S0042-96862004000100006

Jorba, J., Diop, O. M., Iber, J. (2016). Update on vaccine-derived polioviruses  Worldwide, January 2015–May 2016. MMWR, 65 (30), 763-769.

Global Polio Eradication Initiative (2015). Reporting and classification of vaccinederived polioviruses.  http://www.polioeradication.org/ Portals/0/ Document/Resources/ VDPV_ReportingClassification.pdf

WHO. (2016). Update on vaccine-derived polioviruses worldwide, January 2015–May 2016. Weekly Epidemiological Record, 91(31), 365-375.

Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine  worldwide, 2013-2016. (2015). MMWR. 64(25), 699-702.

WHO. (2016). Cessation of use of trivalent oral polio vaccine and introduction of inactivated poliovirus vaccine worldwide, 2016. Weekly Epidemiological Record, 91(36/37), 421-427.

Famulare, M., Chang, S., Iber J. (2015). Sabin vaccine reversion in the field: a comprehensive analysis of sabin-like poliovirus isolates in Nigeria. J. Virol., 90(1), 317-331.

Ecale Zhou, C. L. (2016). S2M: A stochastic simulation vodel of poliovirus genetic state transition. Bioinform. Biol. Insights, (10), 81-95.

WHO: Global Polio Eradication Initiative (2012). 7th meeting of the Independent Monitoring Board. Weekly Epidemiological Record., 87(51/52), 509-512.

WHO. (2016). Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2016. Weekly Epidemiological Record, 91(36/37), 427-432.

Zadorozhna, V .I., Frolov, A. F., Zubkova, N. L. (2012). Poliomiyelit: imunoprofilaktyka ta yiyi vplyv na evolyutsiyu epidemichnoho protsesu. K.: DIA.

Moyseyeva, H. V. (2002). Kharakterystyka imunoprofilaktyky poliomiyelitu v Ukrayini ta otsinka efektyvnosti vykorystannya inaktyvovanoyi poliomiyelitnoyi vaktsyny. Avtoref. … dys. kand. med. nauk. K.

Torbenko, V. V. (2001). Otsinka efektyvnosti suchasnoho epidemiolohichnoho nahlyadu za poliomiyelitom v umovakh yoho eradykatsiyi. Avtoref. … dys. kand. med. nauk. K.

Orenstein, W. A. (2015). Eradicating polio: how the world's pediatricians can help stop this crippling illness forever. Pediatrics, 135(1), 196-202.

Korotkova, E. A., Gmyl, A. P., Yakovenko, M. L. (2016). A cluster of paralytic poliomyelitis cases due to transmission of slightly diverged Sabin 2 vaccine poliovirus. J Virol., 90 (13), 5978-5988.

Published

2017-02-10

How to Cite

Zadorozhna, V. Z., & Tsyganchuk, O. M. (2017). POLIO: NEW CHALLENGES ON THE WAY TO ERADICATION. Infectious Diseases – Infektsiyni Khvoroby, (4), 5–12. https://doi.org/10.11603/1681-2727.2016.4.7206

Issue

Section

Editorial